Physician profile
Samir S Awad
NPI 1922103290
$1,576,630.04
in general payments reported to CMS, 2019-2025
20 companies · $170K in 2025
The $170K reported for 2025 was more than what 99% of Surgical Critical Care providers received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143K · 2020: $105K · 2021: $303K · 2022: $420K · 2023: $296K · 2024: $138K · 2025: $170K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $461K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Travel and Lodging: $40K · Honoraria: $13K · Food and Beverage: $6,357 · Debt Forgiveness: $3,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $461,015.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,813.75 |
| Travel and Lodging | $40,183.68 |
| Honoraria | $13,499.00 |
| Food and Beverage | $6,357.29 |
| Debt Forgiveness | $3,402.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $855,894.58 | 2019-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Sanara Medtech INC. | $238,709.03 | 2020-2025 | Celleraterx, Celleraterx, Biasurge |
| Triad Life Sciences INC. | $106,339.54 | 2021-2022 | |
| Aroa Biosurgery Incorporated | $99,278.58 | 2022-2025 | |
| La Jolla Pharmaceutical Company | $79,723.10 | 2019-2025 | Giapreza, Zevtera, Xerava |
| Convatec INC. | $58,147.97 | 2023-2025 | |
| Wound Management Technologies, INC | $49,204.14 | 2019 | |
| Biom'Up France Sas | $37,170.11 | 2020-2021 | |
| Next Science LLC | $20,250.00 | 2020-2021 | |
| Biom'Up Sa | $15,673.37 | 2019 | |
| Integra Lifesciences Corporation | $13,381.28 | 2019-2020 | |
| Intuitive Surgical, INC. | $1,454.50 | 2019 | |
| Tas Medical, INC. | $436.70 | 2024 | |
| Covidien Lp | $325.00 | 2020 | |
| Medtronic, INC. | $325.00 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $134.98 | 2022 | |
| Tei Biosciences INC | $57.76 | 2019 | |
| W. L. Gore & Associates, INC. | $52.33 | 2021 | |
| Masimo Corporation | $37.67 | 2022 | |
| Smith+Nephew, INC. | $34.40 | 2025 | Renasys Touch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Awad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.